Rønn A M, Mutabingwa T K, Kreisby S, Angelo H R, Fuursted K, Bygbjerg I C
Department of Infectious Diseases, Rigshospitalet/Centre for Medical Parasitology, Copenhagen, Denmark.
Ther Drug Monit. 1999 Dec;21(6):609-14. doi: 10.1097/00007691-199912000-00005.
A high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of trimethoprim (TMP), sulphamethoxazole (SMX), and acetylsulphamethoxazole (AcSMX) in small amounts of blood. The method involved precipitation with 50 microL trichloracetic acid (1M) to 125 microL plasma or serum sample. 60 microL supernatant was added to 60 microL mobile phase, modified with 50microL 1 M sodium hydroxide/mL. The mobile phase consisted of 20% acetonitrile and 80% phosphate buffer adjusted to pH 6.15. Using 125 microL of the sample, limits of quantitation were 0.1 microg/mL for TMP, 1.0 microg/mL for SMX, and 1.0 microg/mL for AcSMX. The precision of the method was 2% to 11% over the range of concentrations tested, 0.5-30 microg/mL for TMP, 5-300 microg/mL for SMX, and 2.5-150 microg/mL for AcSMX, respectively. No interference with other commonly used drugs was observed. The method is rapid, simple, specific, and sensitive enough for pharmacokinetic studies. The small amount of blood required makes it suitable for pediatric patients. The method was used to analyze samples from Tanzanian children aged 6-59 months participating in a cotrimoxazole (TMP/SMX)/chloroquine randomized trial for the treatment of uncomplicated malaria. Venous blood samples from 68 children were collected 2 hours after the first dose of TMP/SMX (4 mg/kg TMP/20 mg/kg SMX at two divided doses for 5 days) and again at treatment day 4. Individual variations in plasma concentrations of TMP, SMX, and AcSMX were considerable. The mean and SEM plasma concentrations (g/mL) of TMP, SMX, and AcSMX 2 hours after the first treatment dose were 2.0 +/- 1.0 (range 0.5-6), 53 +/- 22 (range 24-146), and 13.5 +/- 12 (range 0-65), respectively. On the fourth day the attained plasma concentrations were not significantly different from samples collected after the first dose.
建立了一种高效液相色谱(HPLC)法,用于同时分析少量血液中的甲氧苄啶(TMP)、磺胺甲恶唑(SMX)和乙酰磺胺甲恶唑(AcSMX)。该方法包括向125μL血浆或血清样品中加入50μL三氯乙酸(1M)进行沉淀。将60μL上清液加入到60μL用50μL 1M氢氧化钠/mL改性的流动相中。流动相由20%乙腈和80%pH值调至6.15的磷酸盐缓冲液组成。使用125μL样品时,TMP的定量限为0.1μg/mL,SMX为1.0μg/mL,AcSMX为1.0μg/mL。在所测试的浓度范围内,该方法的精密度为2%至11%,TMP的浓度范围为0.5 - 30μg/mL,SMX为5 - 300μg/mL,AcSMX为2.5 - 150μg/mL。未观察到与其他常用药物的干扰。该方法快速、简单、特异且灵敏,足以用于药代动力学研究。所需血量少,适用于儿科患者。该方法用于分析参与复方新诺明(TMP/SMX)/氯喹治疗单纯性疟疾随机试验的6 - 59个月坦桑尼亚儿童的样本。在首次服用TMP/SMX(4mg/kg TMP/20mg/kg SMX,分两次给药,共5天)后2小时,收集68名儿童的静脉血样本,并在治疗第4天再次收集。TMP、SMX和AcSMX血浆浓度的个体差异相当大。首次治疗剂量后2小时,TMP、SMX和AcSMX的平均血浆浓度及标准误(g/mL)分别为2.0±1.0(范围0.5 - 6)、53±22(范围24 - 146)和13.5±12(范围0 - 65)。在第4天,达到的血浆浓度与首次给药后收集的样本无显著差异。